Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: J Surg Res. 2013 Oct 21;187(2):412–426. doi: 10.1016/j.jss.2013.10.032

Figure 7.

Figure 7

Intratumoral M51R-VSV treatment of pancreatic cancer xenografts derived from VSV-sensitive MiaPaCa2 and VSV-resistant Panc 03.27 cells. Subcutaneous xenografts were established in the right flank of athymic nude mice. Once palpable tumors formed, the mice were randomly assigned to a single intratumoral injection of 1×108 pfu M51R-VSV (n=10) or culture medium as negative controls (n=9). Tumor volume was measured with calipers. Tumor growth is presented as the percentage of tumor size on day 0 post-infection and is expressed as the mean ± standard error of the mean. P-values shown represent the difference in percent change in tumor growth between M51R-VSV treated and mock-treated xenografts at post-treatment day 30.